| アブストラクト | INTRODUCTION: beta-Blockers are essential for cardiovascular disease management but can induce respiratory issues, particularly with non-selective beta-blockers. Their safety in asthmatic patients is debated. OBJECTIVE: This study investigates the link between different classes of beta-blockers and the risk of asthma and asthma-like adverse events (AEs) using data from the Food and Drug Administration's Adverse Event Reporting System (FAERS). METHODS: beta-Blockers were first reviewed according to European Society of Cardiology classification and then using the Vashistha and Kumar classification. The risk associated with different beta-blocker classes was evaluated through disproportionality analysis using the reporting odds ratio (ROR). RESULTS: Among 251,145 AEs reported for beta-blockers, 4104 were asthma-related. Selective beta(1)-blockers had a higher asthma risk signal (ROR: 1.15) compared to non-selective beta-blockers (ROR: 0.90). alpha- and beta-Blockers showed the lowest risk (ROR: 0.51). The Vashistha and Kumar classification detailed risk profiles for various beta-blockers, highlighting differences even within the same class. Dual alpha- and beta-blockers, hydrophilic, and lipophilic beta-blockers posed lower asthma risks, while selective beta(1)-blockers had higher risks regardless of intrinsic sympathomimetic activity. CONCLUSION: Although the signals detected by disproportionality analysis are only candidate risks, the risk stratification resulting from our analysis highlights the need for cautious beta-blocker selection in asthmatic patients or those predisposed to asthma. Furthermore, despite the limitations associated with the FAERS data, the study reveals significant variability in risk among different beta-blocker classes, crucial for clinical decisions and patient management. Drugs like esmolol, metoprolol, nebivolol, and nadolol may be safer for asthmatic patients, whereas betaxolol, bisoprolol, timolol, and propranolol should be avoided. |
|---|
| ジャーナル名 | Respiratory medicine |
|---|
| Pubmed追加日 | 2024/11/4 |
|---|
| 投稿者 | Cazzola, Mario; Ora, Josuel; Calzetta, Luigino; Rogliani, Paola; Matera, Maria Gabriella |
|---|
| 組織名 | Unit of Respiratory Medicine, Department of Experimental Medicine, University of;Rome 'Tor Vergata', Rome, Italy. Electronic address: mario.cazzola@uniroma2.it.;Division of Respiratory Medicine, University Hospital Policlinico 'Tor Vergata',;Rome, Italy.;Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit,;University of Parma, Parma, Italy.;Rome 'Tor Vergata', Rome, Italy; Division of Respiratory Medicine, University;Hospital Policlinico 'Tor Vergata', Rome, Italy.;Unit of Pharmacology, Department of Experimental Medicine, University of Campania;'Luigi Vanvitelli', Naples, Italy. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39490635/ |
|---|
